BioStockInfo · catalyst calendar
/
← Catalyst calendar

ODTX biotech catalysts & pipeline

ODYSSEY THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

OD-001 — Topline data

H2 2027

• OD-001 (RIPK2 scaffolding inhibitor): Initiate a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both studies expected in the second half of 2027.
Source filing

OD-001 — Conference presentation

Oct 17–Oct 20

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October
Source filing

Explore the free biotech catalyst calendar